Lacrimal Duct Stent Tube Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 5.20 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Lacrimal Duct Stent Tube Market Analysis
The lacrimal duct stent tube market is anticipated to record a CAGR of 5.2% over the forecast period.
The COVID-19 pandemic presented significant hurdles for the healthcare sector. Since the majority of surgical procedures were considered to be non-urgent, all outpatient consultations were delayed or restricted during the COVID-19 pandemic to lower the danger of viral transmission. Thus, the lacrimal duct stent market was adversely impacted during the pandemic. However, it is expected to gain traction in the post-pandemic era due to the resumption of surgical procedures.
Certain factors that are driving the market include the increasing patient pool for nasolacrimal duct obstruction and rising demand for treatments with minimal invasions and better success rates. Nasolacrimal duct obstruction (NLDO) or dacryostenosis is the most common disorder of the lacrimal system. According to the August 2022 updated report, published by the NCBI, congenital nasolacrimal duct obstruction may occur in 3-6% of newborns, while it occurs bilaterally in 20% of newborns. There is a high rate of spontaneous resolution of congenital nasolacrimal duct obstruction, with approximately 70% of affected children being free of the symptoms by 3 months of age, and over 90% recovering by their first birthday. However, infants at increased risk for this condition include those with trisomy 21, ectrodactyly-ectodermal dysplasia-cleft lip/palate (EEC) syndrome, branchiooculofacial syndrome, CHARGE (coloboma, heart anomaly, choanal atresia, and retardation, genital, and ear anomalies) syndrome, and Goldenhar syndrome. Hence, the rising prevalence of such health conditions is expected to drive the market over the forecast period.
New studies on lacrimal stent tubes help expand the applications for various conditions, which is expected to boost the market's growth over the forecast period. For instance, as per the study published by the European Journal of Ophthalmology in December 2021, lacrijet monocanalicular stent intubation has a high rate of success, shortens the surgical time, and has a low rate of complications in children with congenital nasolacrimal duct obstruction. Hence, the new studies on lacrimal stent tubes expand the indications and provide the safety and efficacy of the stents, which may drive the market over the forecast period.
However, complications associated with stent tubes are likely to hinder the growth of the market over the forecast period.
Lacrimal Duct Stent Tube Market Trends
This section covers the major market trends shaping the Lacrimal Duct Stent Tube Market according to our research experts:
Bicanalicular Lacrimal Duct Stent Tube is Expected to Hold Significant Share in the Market During the Forecast Period
Bicanalicular lacrimal intubation is a successful treatment for children with nasolacrimal duct obstruction, and the younger the age of the children, the higher the success rate. Bicanalicular lacrimal tubes have two probes with an intervening stent. One probe is passed through the upper punctum and the other through the lower punctum. The probes are removed, and the free ends of the silicone tube are tied in the nose and sometimes secured with a suture. The longer the duration of the tube retention, the better the results, with the best results between 3 and 12 months. The increased research funding on eye disorders increases the scope and usage of the eye-related devices like bicanalicular lacrimal ducts stent tubes, which may drive the market over the forecast period.
The studies showing the reduced complications of bicanalicular stents are boosting the usage of these stents. For instance, as per the report published by the Journal of Ophthalmology in March 2021, silicone tube repositioning guiding by using a memory wire probe is an optional technique in the treatment of prolapse of silicone tubes in bicanalicular nasal iintubation.
The comparative studies of bicanalicular lacrimal intubation versus monocanalicular lacrimal intubation help reveal the advantages of bicanalicular lacrimal intubation over monocanalicular lacrimal intubation, which is expected to drive the market's growth through this segment. For instance, as per the study published by Frontiers in July 2022, endoscopic dacryocystorhinostomy with pushed bicanalicular intubation is easily manipulated and has a promising surgical outcome over pulled monocanalicular intubation. Hence, the better outcomes of bicanalicular intubation using a stent tube are expected to drive the market over the forecast period.
North America is Expected to Have Significant Growth in the Market Over the Forecast Period
North America is expected to have significant growth in the overall market throughout the forecast period. The United States holds the largest market share due to better regulations of surgical devices and growing awareness among the population to approach such procedures in case of lacrimal duct obstruction and other associated problems. The companies in the country also have well-established direct channel collaborations with hospitals and clinics.
The high burden of nasolacrimal duct obstruction and new studies using lacrimal sten tubes in the region are boosting the demand for lacrimal stents in the region, thus driving the market in the region. As per the report published by the American Academy of Ophthalmology in November 2022, congenital nasolacrimal duct obstruction occurs in approximately 5% of normal newborn infants, and the blockage occurs most commonly at the valve of Hasner at the distal end of the duct. Hence, the high burden of congenital nasolacrimal duct obstruction increases the demand for a lacrimal stent for maintenance.
The new studies on lacrimal stents reveal the comparative efficacy of products that can impact the market's growth. For instance, as per the study report published by IOVS Journal in June 2021, both the Crawford and Nunchaku style lacrimal stents showed equivalent rates of improvement in epiphora during the short- and long-term follow-up visits. Hence, the stent studies help find out the efficacy of the products in the management of lacrimal disorders, which may also drive the market over the forecast period.
Lacrimal Duct Stent Tube Industry Overview
The lacrimal duct stent tube market is consolidated and consists of very few major players. Companies like Aurolab, Bess Medizintechnik GmbH, ZEISS (FCI Ophthalmics), Gunther Weiss Scientific Glassblowing Co. Inc., and Kaneka Pharma America LLC hold a substantial market share.
Lacrimal Duct Stent Tube Market Leaders
ZEISS (FCI Ophthalmics)
Aurolab
bess medizintechnik gmbh
Kaneka Medical America LLC
Gunther Weiss Scientific Glassblowing Co., Inc.
*Disclaimer: Major Players sorted in no particular order
Lacrimal Duct Stent Tube Market News
- In May 2022, AffaMed Therapeutics held a DEXTENZA launch and Advisory Board Meeting in Macau. DEXTENZA resorbs and exits the nasolacrimal system without the need for removal.
- In February 2021, FCI Ophthalmics launched the LacriJet in the United States. It is the first, self-retaining monocanalicular nasolacrimal intubation preloaded on a single-use injector, according to FCI Ophthalmics.
Lacrimal Duct Stent Tube Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Patient Pool for Nasolacrimal Duct Obstruction
4.2.2 Rising Demand for Treatments with Minimal Invasions and Better Success Rates
4.3 Market Restraints
4.3.1 Complications Associated with Stent Tubes
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Product Type
5.1.1 Monocanalicular Lacrimal Duct Stent Tube
5.1.2 Bicanalicular Lacrimal Duct Stent Tube
5.2 By End User
5.2.1 Hospitals
5.2.2 Ophthalmic Clinics
5.2.3 Other End Users
5.3 By Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Aurolab
6.1.2 Bess Medizintechnik GmbH
6.1.3 ZEISS (FCI Ophthalmics)
6.1.4 Gunther Weiss Scientific Glassblowing Co. Inc.
6.1.5 Kaneka Medical America LLC
6.1.6 BD (Becton, Dickinson and Company)
6.1.7 BVI Medical Inc.
6.1.8 Walsh Medical Devices Inc.
6.1.9 Surtex Instruments Limited
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Lacrimal Duct Stent Tube Industry Segmentation
As per the scope of the report, a lacrimal stent is a hollow silicone tubing with a non-traumatic tip. The tubing is securely attached to malleable stainless steel probes that are used to guide the silicone tubing through the lacrimal drainage apparatus. Lacrimal stents are used to reduce the risk of recurrent stenosis of the nasolacrimal duct.
The lacrimal duct stent tube market is segmented by product type (monocanalicular lacrimal duct stent tube and bicanalicular lacrimal duct stent tube), end user (hospitals, ophthalmic clinics, and other end users), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Product Type | |
| Monocanalicular Lacrimal Duct Stent Tube | |
| Bicanalicular Lacrimal Duct Stent Tube |
| By End User | |
| Hospitals | |
| Ophthalmic Clinics | |
| Other End Users |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Lacrimal Duct Stent Tube Market Research FAQs
What is the current Lacrimal Duct Stent Tube Market size?
The Lacrimal Duct Stent Tube Market is projected to register a CAGR of 5.20% during the forecast period (2024-2029)
Who are the key players in Lacrimal Duct Stent Tube Market?
ZEISS (FCI Ophthalmics), Aurolab, bess medizintechnik gmbh, Kaneka Medical America LLC and Gunther Weiss Scientific Glassblowing Co., Inc. are the major companies operating in the Lacrimal Duct Stent Tube Market.
Which is the fastest growing region in Lacrimal Duct Stent Tube Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Lacrimal Duct Stent Tube Market?
In 2024, the North America accounts for the largest market share in Lacrimal Duct Stent Tube Market.
What years does this Lacrimal Duct Stent Tube Market cover?
The report covers the Lacrimal Duct Stent Tube Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Lacrimal Duct Stent Tube Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Lacrimal Duct Stent Tube Industry Report
Statistics for the 2024 Lacrimal Duct Stent Tube market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Lacrimal Duct Stent Tube analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
